Latest Conference Articles

February 21st 2015, 2:06pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Jeffrey Jones, MD, presented evidence supporting the integration of obinutuzumab, ibrutinib, ofatumumab, and idelalisib into the frontline setting for patients with chronic lymphocytic leukemia.

February 21st 2015, 1:46pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Although treatments and cure rates have increased significantly over the past 60 years for patients with Hodgkin lymphoma, it is crucial that practitioners stay up-to-date on research that can affect outcomes for their patients with this uncommon form of cancer.

February 21st 2015, 11:14am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Standard chemotherapy remains part of the treatment paradigm for patients with chronic lymphocytic leukemia but its role is undergoing a major shift as significant advances are being made in novel therapies.

February 20th 2015, 4:02pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.

February 20th 2015, 2:56pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

The treatment options for patients with relapsed/refractory multiple myeloma are expanding rapidly, notably through clinical trial evidence supporting a number of three-drug combination regimens, according to Sundar Jagannath, MD.

February 20th 2015, 1:46pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

The indolent nature of follicular lymphoma and the range of treatment options currently available or in development may create complicated questions regarding how to best use and sequence these therapies.

February 20th 2015, 12:03pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Steven Treon, MD, PhD, from the Dana-Farber Cancer Institute, discusses the game-changing discoveries in Waldenstrom's Macroglobulinemia that led to the approval of ibrutinib for treatment of the disease.

February 20th 2015, 10:05am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses the recent approval of lenalidomide as a therapy for patients with multiple myeloma.

February 20th 2015, 8:12am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia.

February 20th 2015, 7:11am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

February 11th 2015, 2:29pm

PER® New York Lung Cancer Symposium

Abraham Chachoua, MD, associate director of cancer services at NYU Langone Medical Center, talks about targeted treatment for mutations in non-small cell lung cancer and adenocarcinoma.

January 21st 2015, 10:21am

Gastrointestinal Cancers Symposium (ASCO GI)

Treatment with a multitargeted tyrosine kinase inhibitor led to a small but statistically significant improvement in progression-free survival (PFS) in patients with advanced, previously treated metastatic colorectal cancer.

January 20th 2015, 11:14am

ASH Annual Meeting and Exposition

Results from a pair of phase II studies indicate that adding the immunomodulatory agent pomalidomide (Pomalyst) to multiple myeloma regimens improved outcomes for patients who have stopped responding to earlier treatments.

January 20th 2015, 8:09am

ASH Annual Meeting and Exposition

Clinicians who treat patients with multiple myeloma have witnessed a sea change in the past 15 years. Yet another revolution appears right around the corner.

January 18th 2015, 10:20am

Gastrointestinal Cancers Symposium (ASCO GI)

Almost half of patients with borderline resectable or locally advanced pancreatic cancer had objective responses to treatment with an investigational chemokine receptor antagonist.

January 17th 2015, 1:50pm

Gastrointestinal Cancers Symposium (ASCO GI)

Lanreotide improved progression-free survival and resulted in more disease control compared with an observation strategy among patients with pancreatic neuroendocrine tumors.

January 17th 2015, 12:36pm

Gastrointestinal Cancers Symposium (ASCO GI)

An analysis of patients with advanced hepatocellular carcinoma and elevated α-fetoprotein who received second-line ramucirumab showed a significant improvement in overall survival.

January 17th 2015, 12:02pm

Gastrointestinal Cancers Symposium (ASCO GI)

Expanded analysis of the NAPOLI-1 trial's per-protocol population continues to support the benefit of adding the nanoliposomal encapsulation of irinotecan MM-398 to 5-fluorouracil plus leucovorin for the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine.

January 17th 2015, 10:54am

Gastrointestinal Cancers Symposium (ASCO GI)

Two polymorphisms of a vasodilatory enzyme had significant associations with improved survival in liver cancer treated with an inhibitor of vascular endothelial growth factor receptor (VEGFR), data from a retrospective study reported at the 2015 Gastrointestinal Cancers Symposium showed.

January 17th 2015, 10:29am

Gastrointestinal Cancers Symposium (ASCO GI)

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a combination treatment of PF-04136309 with FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma (PC).